A prospective, open-label, multicenter, randomized phase II trial: Sequential therapy with BEvacizumab, RAd001 (everolimus) and AxiTinib in metastatic renal cell carcinoma (mRCC) (BERAT study)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Jan 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Axitinib (Primary) ; Bevacizumab (Primary) ; Everolimus (Primary) ; Interferon alpha-2a (Primary) ; Pazopanib; Sorafenib; Sunitinib
Indications Renal cell carcinoma
Focus Biomarker; Therapeutic Use
Acronyms BERAT

19 Jan 2022 Status changed from recruiting to discontinued, as per results published in the Oncology Research and Treatment
19 Jan 2022 Results published in the Oncology Research and Treatment
21 Nov 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01731158).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com